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Fructose bisphosphate aldolase (FBPA) enzymes have been found in a broad
range of eukaryotic and prokaryotic organisms. FBPA catalyses the cleavage
of fructose 1,6-bisphosphate into glyceraldehyde 3-phosphate and dihydroxy-
acetone phosphate. The SSGCID has reported several FBPA structures from
pathogenic sources, including the bacterium Brucella melitensis and the
protozoan Babesia bovis. Bioinformatic analysis of the Bartonella henselae
genome revealed an FBPA homolog. The B. henselae FBPA enzyme was
recombinantly expressed and puriﬁed for X-ray crystallographic studies. The
puriﬁed enzyme crystallized in the apo form but failed to diffract; however, well
diffracting crystals could be obtained by cocrystallization in the presence of the
native substrate fructose 1,6-bisphosphate. A data set to 2.35 A ˚ resolution was
collected from a single crystal at 100 K. The crystal belonged to the ortho-
rhombic space group P212121, with unit-cell parameters a = 72.39, b = 127.71,
c = 157.63 A ˚ . The structure was reﬁned to a ﬁnal free R factor of 22.2%. The
structure shares the typical barrel tertiary structure and tetrameric quaternary
structure reported for previous FBPA structures and exhibits the same Schiff
base in the active site.
1. Introduction
1.1. SSGCID
The Seattle Structural Genomics Center for Infectious Disease
(SSGCID) is one of two consortia funded by NIAID to apply
genome-scale approaches to the solution of protein structures from
biodefense organisms, as well as those causing emerging and re-
emerging diseases. In its ﬁrst three and a half years, the SSGCID has
submitted  350 protein structures to the Protein Data Bank (PDB)
and is on track to solve a further 100 per year going forward. For
several organisms, this represents the majority of PDB submissions
during this time, including 100% of the structures for Ehrlichia,
Anaplasma and Burkholderia. SSGCID’s target-selection strategy
has focused on drug targets, essential enzymes, virulence factors and
vaccine candidates from a number of bacterial (Bartonella, Brucella,
Ehrlichia, Anaplasma, Rickettsia, Burkholderia, Borrelia and Myco-
bacterium) and eukaryotic (Babesia, Cryptosporidium, Toxoplasma,
Giardia, Entamoeba, Coccidioides and Encephalitozoon) pathogens,
as well as ssDNA and negative-strand ssRNAviruses. More than 3000
targets have been selected to date, with >700 proteins being puriﬁed
for crystallization trials. Crystallization screening and analysis of
X-ray diffraction data sets for structure solution are performed at
Emerald BioStructures.
1.2. Aldolase
Aldolases (EC 4.1.2) are enzymes that cleave aldols and have been
the subject of crystallographic study since 1971 (Heidner et al., 1971).
To date, more than 70 unique aldolase structures have been deposited
in the PDB. The glycolytic enzyme fructose bisphosphate aldolase
(EC 4.1.2.13) catalyzes the aldol cleavage of fructose 1,6-bisphos-
phate into dihydroxyacetone phosphate and glyceraldehyde 3-phos-
phate. It also catalyzes the reverse reaction. The hallmark of a class I
aldolase is the presence of an active-site lysine residue which forms a
Schiff base with the substrate.Bartonella henselae is best known for causing cat scratch disease
(CSD). It is a Gram-negative aerobic rod-shaped proteobacterium.
Immunocompromised patients can develop severe complications
from B. henselae. Here, we present the crystal structure of the class I
fructose bisphosphate aldolase from B. henselae with the reactant
bound at the active site.
2. Materials and methods
All expression clones, puriﬁed proteins and protein structures
produced by SSGCID are available to the scientiﬁc community.
2.1. Protein purification and crystallization
2.1.1. Purification of B. henselae aldolase. The protein was
expressed in Escherichia coli using BL21 (DE3) R3 Rosetta cells and
autoinduction medium in a LEX Bioreactor. Starter cultures of LB
broth with appropriate antibiotics were grown for  18 h at 310 K as
described by Choi et al. (2011). ZYP-5052 auto-induction medium
with tryptone, yeast extract, glucose and  -lactose supplemented with
MgSO4 and trace metals was freshly prepared as per Studier’s
published protocol (Studier, 2005). Antibiotics (carbenicillin/ampi-
cillin) were added to 2 l bottles of sterile auto-induction medium. The
medium was inoculated with all of the overnight culture. Inoculated
bottles were then placed into a LEX bioreactor. Cultures were grown
for  24 h at 298 K; the temperature was then reduced to 288 K and
growth continued for a further  72 h. To harvest, the medium was
centrifuged at 4000g for 20 min at 277 K. The cell paste was ﬂash-
frozen in liquid nitrogen and stored at 193 K. The frozen cells were
resuspended in lysis buffer [25 mM HEPES pH 7.0, 500 mM NaCl,
5% glycerol, 30 mM imidazole, 0.025% sodium azide, 0.5% CHAPS,
10 mM MgCl2,1 m M tris(2-carboxyethyl)phosphine (TCEP),
250 ng ml
 1 4-(2-aminoethyl)benzenesulfonyl ﬂuoride hydrochloride
(AEBSF) and 0.05 mgm l
 1 lysozyme]. The resuspended cell pellet
was disrupted on ice for 30 min with a Virtis sonicator (408912; 100 W
power, with alternating cycles of 15 s pulse-on and 15 s pulse-off).
The cell debris was incubated with 20 ml Benzonase nuclease
(25 units ml
 1) at room temperature for 45 min and clariﬁed by
centrifugation on a Sorvall SLA-1500 at 14 000 rev min
 1 for 75 min
at 277 K. The protein was puriﬁed from the clariﬁed cell lysate by
immobilized metal-afﬁnity chromatography on a HisTrap FF 5 ml
column (GE Healthcare) equilibrated with binding buffer (25 mM
HEPES pH 7.0, 500 mM NaCl, 5% glycerol, 30 mM imidazole,
0.025% sodium azide, 1 mM TCEP). The recombinant protein was
eluted with 250 mM imidazole. The puriﬁcation tag (MAHHHHH-
HMGTLEAQTQGPGS) was cleaved with 3C protease, leaving a
GPGS remnant. The sample was further polished using size-exclusion
chromatography (SEC) on a HiLoad 26/60 Superdex 75 column (GE
Healthcare) in SEC buffer (25 mM HEPES pH 7.0, 500 mM NaCl,
2m M DTT, 0.025% sodium azide, 5% glycerol). Fractions from a
single peak were pooled. The protein was concentrated to 21 mg ml
 1
using 10K Amicon Ultra centrifugal ﬁlters (Millipore). The concen-
tration was determined by measuring the OD280 of the protein
(extinction coefﬁcient 29 450 M
 1 cm
 1; molecular weight 39 495 Da)
with a Nanodrop 1000 instrument. The concentrated sample was
ﬂash-frozen in liquid nitrogen and stored at 193 K. This puriﬁcation
yielded 17 mg protein per litre of cell culture with >95% purity.
2.1.2. Crystallization of B. henselae aldolase with the native
substrate fructose 1,6-bisphosphate. B. henselae fructose bisphos-
phate aldolase (BhFBPA) was initially crystallized in the apo form,
but these crystals did not diffract. Crystallization screening was
repeated in the presence of the natural substrate fructose 1,6-bis-
phosphate (FBP), which yielded crystals that diffracted to 2.35 A ˚
resolution at a synchrotron-radiation light source. BhFBPA was
cocrystallized via vapor diffusion at 290 K in drops consisting of 0.4 ml
protein solution and 0.4 ml precipitant solution, with 80 ml precipitant
solution in the reservoir. Protein at 21 mg ml
 1 in SEC buffer was
supplemented with fructose 1,6-bisphosphate (FBP) from a 100 mM
aqueous stock to give a ﬁnal FBP concentration of 10 mM and a ﬁnal
protein concentration of  19 mg ml
 1. A number of crystals grew,
ranging in size from approximately 50 to 200 mm. The precipitant
consisted of 0.2 M sodium acetate, 0.1 M Tris pH 8.5, 30% PEG 4000
(condition B10 of Crystal Screen HT from Hampton Research). The
cryoprotection solution consisted of 80% precipitant solution and
20% ethylene glycol. The crystal used for data collection was soaked
in this cryoprotection solution for  15 s before being ﬂash-cooled in
liquid nitrogen.
2.1.3. Data collection, processing, structure solution and refine-
ment. Data were collected on ALS beamline 5.0.1 as part of the
Collaborative Crystallography Program over a 35 min period. The
wavelength was 0.97740 A ˚ and the detector was an ADSC Q315
CCD. The crystal-to-detector distance was 350 mm. 220 frames were
collected with a width of 1  in ’ at 100 K.
All data were indexed, integrated and scaled with the XDS
suite (Kabsch, 2010). Data-collection and processing statistics are
presented in Table 1. Reﬁnement and validation parameters are
presented in Table 2.
The structure was solved by molecular replacement with Phaser
(McCoy et al., 2007) using a search model prepared from residues
11–343 of Babesia bovis aldolase (PDB entry 3kx6; SSGCID,
unpublished work) with the CCP4i (Winn et al., 2011) interface to
CHAINSAW (Stein, 2008), which uses an alignment between the
target sequence and that of a homologous protein of known crystal
structure to create an improved molecular-replacement model by
truncation of non-identical side chains. The structure was rebuilt
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Table 1
Data-collection statistics.
Values in parentheses are for the highest of 20 resolution shells.
Space group P212121
Unit-cell parameters (A ˚ ) a = 72.39, b = 127.71, c = 157.63
Resolution range 50–2.35 (2.41–2.35)
Unique reﬂections 61670 (4530)
Multiplicity 8.9 (8.4)
Completeness (%) 100 (99.0)
Rmerge† (%) 9.9 (55.3)
Mean I/ (I) 19.5 (4.2)
† Rmerge =
P
h
P
i jIiðhÞ h IðhÞij=
P
h
P
i IiðhÞ.
Table 2
Reﬁnement and model statistics.
Values in parentheses are for the highest of 20 resolution shells.
Resolution range (A ˚ ) 50–2.35 (2.41–2.35)
Rcryst† 0.177 (0.233)
Rfree† 0.222 (0.272)
R.m.s.d. bonds (A ˚ ) 0.010
R.m.s.d. angles ( ) 1.180
Protein atoms 10241
Nonprotein atoms 574
Mean B factor (A ˚ 2) 26.95
Ligand B factor (A ˚ 2) 33.2
Residues in favored region (%) 97.56
Residues in allowed region (%) 99.7
MolProbity score [percentile] 1.50 [99th]
PDB code 3mmt
† Rcryst =
P
hkl
   jFobsj j Fcalcj
   =
P
hkl jFobsj. The free R factor was calculated using the 5%
of the reﬂections that were omitted from the reﬁnement.in Coot (Emsley & Cowtan, 2004) and reﬁned with REFMAC5
(Murshudov et al., 2011) using two TLS groups per monomer. Figures
were prepared with PyMOL (http://www.pymol.org).
3. Results and discussion
3.1. Overall structure
BhFBPA crystallized with four monomers in the asymmetric unit
(50% solvent content; Matthews coefﬁcient VM =2 . 4 5 A ˚ 3 Da
 1;
Matthews, 1968). BhFBPA adopts the typical TIM-barrel fold tertiary
structure of aldolases as well as the typical homotetrameric assembly
quaternary structure, with an r.m.s. difference for monomer A of
0.94 A ˚ from the 3kx6 starting model. It has  50% sequence identity
to many aldolases with unsolved structures, such as those from
Toxoplasma gondii, Arabidopsis thaliana and Cryptosporidium
parvum. The ﬁnal FBP-bound model contains four copies of FBPA
including three residues of the four-residue N-terminal puriﬁcation
tag and residues 1–340 (of 343) of the protein; the FBP ligand was
modelled in each monomer. 498 water molecules were modelled.
The ﬁnal model showed good geometry (Table 2) as determined
using the program MolProbity (Chen et al., 2010).
3.2. Reactant state
As part of glycolysis, FBPA catalyzes the cleavage of fructose
1,6-bisphosphate (FBP) into glyceraldehyde 3-phosphate and dihy-
droxyacetone phosphate (DHAP). Here, we determined the 2.35 A ˚
resolution crystal structure of BhFBPA (Tables 1 and 2). This struc-
ture has clear electron density for FBP bound at the active site
(Fig. 1). There is a covalent bond between C atom C2 of the linear
FBP molecule and the N
  atom of Lys223 of the protein. Further-
more, phosphate group 1 of FBP makes hydrogen bonds to three
amide N atoms as well as the side chains of Arg295 and Ser264
(Fig. 2). The alcohol groups along the linear carbon backbone of FBP
also make hydrogen bonds to the side chains of the protein, as well as
to nearby water molecules. Finally, the O atoms of phosphate group 2
are hydrogen bonded to side chains and to nearby water molecules.
SSGCID’s interest in BhFBPA is as a potential drug target. We
compared the active site of BhFBPA with those of homologous
mammalian enzymes. The orientation of the FBP molecule in the
active site differs from that observed in the structure of human
muscle aldolase (PDB entry 4ald; Dalby et al., 1999; 54% sequence
identity; r.m.s.d. of non-H atoms in the FBP ligand of 2.2 A ˚ ; r.m.s.d.
for C
  atoms over the whole protein of 0.663 A ˚ ). However, the
complex observed in 4ald does not show full formation of the Schiff
base, suggesting that the state in 4ald precedes the formation of
the covalent complex (Dalby et al., 1999). The FBP conformation in
BhFBPA is essentially identical to that of rabbit muscle aldolase A
(PDB entry 1zai; St-Jean et al., 2005; r.m.s.d. of non-H atoms in the
FBP ligand of 0.29 A ˚ ; r.m.s.d. for C
  atoms over a full monomer of
0.489).
4. Conclusion
The crystal structure of fructose bisphosphate aldolase from
B. henselae was determined in complex with its reactant at 2.35 A ˚
resolution. The structure obtained of the reactant Schiff-base state is
similar to those of other aldolases in the reactant state [PDB entries
1zai (St-Jean et al., 2005), 3mbf (Gardberg et al., 2011) and 2qdg
(Lafrance-Vanasse & Sygusch, 2007)], especially rabbit muscle FBPA
A (PDB entry 1zai). The similarity to the active site of mammalian
FBPA A suggests that the design of a speciﬁc inhibitor for BhFBPA
(that does not inhibit the human enzyme) would be exceptionally
challenging and would have to rely on exploiting very minor differ-
ences in the chemical environment in and near the active site.
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Figure 1
Weighted 2Fo   Fc electron-density map at 1.5  for FBP and nearby residues at
the active site of fructose bisphosphate aldolase from B. henselae. There is clear
electron density for a Schiff base formed between Lys223 and the FBP molecule.
Figure 2
Bonding environment for FBP bound at the active site of fructose bisphosphate
aldolase from B. henselae.References
Chen, V. B., Arendall, W. B., Headd, J. J., Keedy, D. A., Immormino, R. M.,
Kapral, G. J., Murray, L. W., Richardson, J. S. & Richardson, D. C. (2010).
Acta Cryst. D66, 12–21.
Choi, R., Kelley, A., Leibly, D., Nakazawa Hewitt, S., Napuli, A. & Van
Voorhis, W. (2011). Acta Cryst. F67, 998–1005.
Dalby, A., Dauter, Z. & Littlechild, J. A. (1999). Protein Sci. 8, 291–297.
Emsley, P. & Cowtan, K. (2004). Acta Cryst. D60, 2126–2132.
Gardberg, A., Sankaran, B., Davies, D., Bhandari, J., Staker, B. & Stewart, L.
(2011). Acta Cryst. F67, 1055–1059.
Heidner, E. G., Weber, B. H. & Eisenberg, D. (1971). Science, 171, 677–679.
Kabsch, W. (2010). Acta Cryst. D66, 125–132.
Lafrance-Vanasse, J. & Sygusch, J. (2007). Biochemistry, 46, 9533–
9540.
Matthews, B. W. (1968). J. Mol. Biol. 33, 491–497.
McCoy, A. J., Grosse-Kunstleve, R. W., Adams, P. D., Winn, M. D., Storoni,
L. C. & Read, R. J. (2007). J. Appl. Cryst. 40, 658–674.
Murshudov, G. N., Skuba ´k, P., Lebedev, A. A., Pannu, N. S., Steiner, R. A.,
Nicholls, R. A., Winn, M. D., Long, F. & Vagin, A. A. (2011). Acta Cryst.
D67, 355–367.
Stein, N. (2008). J. Appl. Cryst. 41, 641–643.
St-Jean, M., Lafrance-Vanasse, J., Liotard, B. & Sygusch, J. (2005). J. Biol.
Chem. 280, 27262–27270.
Studier, F. W. (2005). Protein Expr. Purif. 41, 207–234.
Winn, M. D. et al. (2011). Acta Cryst. D67, 235–242.
structural communications
1054 Gardberg et al.   Fructose bisphosphate aldolase Acta Cryst. (2011). F67, 1051–1054